Binds Cancer Cell Or Component Or Product Thereof (e.g., Cell-surface Antigen, Etc.) Patents (Class 530/388.8)
-
Patent number: 8114965Abstract: The invention includes antibodies or antigen-binding fragments thereof which bind specifically to conformational epitopes on the extracellular domain of PSMA, compositions containing one or a combination of such antibodies or antigen-binding fragments thereof, hybridoma cell lines that produce the antibodies, and methods of using the antibodies or antigen-binding fragments thereof for cancer diagnosis and treatment. The invention also includes oligomeric forms of PSMA proteins, compositions comprising the multimers, and antibodies that selectively bind to the multimers.Type: GrantFiled: November 7, 2007Date of Patent: February 14, 2012Assignees: PSMA Development Company, LLC, Amgen Fremont Inc.Inventors: Paul J. Maddon, Gerald P. Donovan, William C. Olson, Norbert Schuelke, Jason Gardner, Dangshe Ma, Jaspal S. Kang, Larry Green
-
Patent number: 8105830Abstract: The present invention relates to polyspecific binding molecules and particularly single-chain polyspecific binding molecules that include at least one single-chain T-cell receptor (sc-TCR) covalently linked through a peptide linker sequence to at least one single-chain antibody (sc-Ab). Further disclosed are methods and compositions for testing and using the molecules.Type: GrantFiled: November 5, 2002Date of Patent: January 31, 2012Assignee: Altor BioScience CorporationInventors: Jon A. Weidanz, Kimberlyn F. Card, Linda A. Sherman, Norman R. Klinman, Hing C. Wong
-
Patent number: 8106170Abstract: The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition resulting from a coronavirus such as SARS-CoV.Type: GrantFiled: November 10, 2005Date of Patent: January 31, 2012Assignee: Crucell Holland B.V.Inventors: Jan Henrik Ter Meulen, Edward Norbert Van Den Brink, Cornelis Adriaan De Kruif, Jaap Goudsmit
-
Patent number: 8101179Abstract: A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.Type: GrantFiled: March 31, 2006Date of Patent: January 24, 2012Assignee: Biomedics Inc.Inventors: Masanori Numazaki, Tetsuo Nakamura, Sadakazu Usuda, Eduardo A. Padlan
-
Patent number: 8101720Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.Type: GrantFiled: January 25, 2008Date of Patent: January 24, 2012Assignee: Xencor, Inc.Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
-
Patent number: 8101372Abstract: The present invention relates to methods and compositions for the diagnosis and therapy of prostate cancer which utilize isolated polynucleotides corresponding to the human SGP28 gene, proteins encoded by the SGP28 gene and fragments thereof, and antibodies capable of specifically recognizing and binding to SGP28 proteins.Type: GrantFiled: December 23, 2008Date of Patent: January 24, 2012Assignee: Agensys, Inc.Inventors: Rene S. Hubert, Arthur B. Raitano, Daniel E. H. Afar, Steve Chappell Mitchell, Mary Faris, Aya Jakobovits
-
Patent number: 8097252Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.Type: GrantFiled: January 6, 2011Date of Patent: January 17, 2012Assignee: Immunomedics, Inc.Inventors: William J. McBride, Chien-Hsing Chang, David M. Goldenberg, Hans J. Hansen
-
Patent number: 8097251Abstract: The present invention relates to functional heavy chain antibodies, functional single domain heavy chain antibodies, functional VH domains, or functional fragments thereof including an amino acid which is neither a charged amino acid nor a C at position 45, and including an amino acid at position 103 independently chosen from the group consisting of R, G, K, S, Q, L, and P, and optionally an amino acid at position 108 independently chosen from the group consisting of Q, L and R, the positions determined according to the Kabat numbering.Type: GrantFiled: June 23, 2006Date of Patent: January 17, 2012Assignee: Vlaams Interuniversitair Instituut Voor Biotechnologie VZWInventors: Serge Muyldermans, Karen Silence
-
Patent number: 8093010Abstract: The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules.Type: GrantFiled: October 29, 2009Date of Patent: January 10, 2012Assignee: Merck Serono S.A.Inventors: Beat A. Imhof, Michel Aurrand-Lions
-
Patent number: 8088896Abstract: The present invention provides novel antibodies and functional fragments thereof specific for CD38, and methods for using the same. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: October 12, 2006Date of Patent: January 3, 2012Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 8088378Abstract: The present invention is directed to anti-CD79b antibody, huMA79b.v28, and compositions of matter thereof useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.Type: GrantFiled: July 15, 2008Date of Patent: January 3, 2012Assignee: Genetech Inc.Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
-
Publication number: 20110318264Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.Type: ApplicationFiled: February 18, 2010Publication date: December 29, 2011Inventors: Ugur Sahin, Özlem Türecl, Michael Koslowski
-
Patent number: 8071815Abstract: The present disclosure provides methods of diagnosing and staging squamous cell carcinomas, for instance head and neck (HNSCC), by detecting chicken ovalbumin upstream promoter-transcription factor-interacting protein 2 (CTIP2) expression. For example, it is demonstrated herein that expression of CTIP2 is increased in SCC relative to a corresponding normal sample. Also included are kits for detecting SCC, as well as methods for identifying CTIP2 inhibitors.Type: GrantFiled: July 17, 2009Date of Patent: December 6, 2011Inventors: Arup Kumar Indra, Gitali Indra, Joseph Abecassis, Mark Leid
-
Patent number: 8071072Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: May 30, 2007Date of Patent: December 6, 2011Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Maximiliano Vasquez
-
Patent number: 8071323Abstract: Antibody compositions and methods for treatment of neoplastic disease in a mammalian subject are provided. Methods of diagnosing cancer in a mammalian subject are also provided.Type: GrantFiled: April 6, 2007Date of Patent: December 6, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dimiter S. Dimitrov, Zhongyu Zhu
-
Patent number: 8067550Abstract: The present invention relates to the production of anti non functional P2X7 receptor monoclonal antibodies from hybridoma cell lines.Type: GrantFiled: October 10, 2007Date of Patent: November 29, 2011Assignee: Biosceptre International LimitedInventors: Julian Alexander Barden, Angus Gidley-Baird
-
Patent number: 8067001Abstract: An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been generated. Methods and uses for the antibodies are detailed including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: June 24, 2010Date of Patent: November 29, 2011Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimishisa Ichikawa, Robert P. Kimberly, William J. Koopman
-
Publication number: 20110287021Abstract: The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.Type: ApplicationFiled: May 19, 2011Publication date: November 24, 2011Applicant: PATRYS LIMITEDInventors: Hans-Konrad Mueller-Hermelink, Heinz Peter Vollmers
-
Patent number: 8062887Abstract: The present invention provides a monoclonal antibody recognizing modification after translation of p53 in a manner specific to a modification site, an antibody microarray comprising the antibody immobilized on a substrate, etc. Disclosed is a monoclonal antibody which reacts specifically with a peptide consisting of an amino acid sequence of at least 6 consecutive amino acids containing a predetermined amino acid residue of the amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid residue is phosphorylated or acetylated, or with a peptide having one to several arbitrary amino acids added to the above peptide, but does not react with the above peptide which is not phosphorylated or acetylated.Type: GrantFiled: March 31, 2006Date of Patent: November 22, 2011Assignees: National University Corporation, Hokkaido University, Genenet Co., Ltd.Inventors: Kazuyasu Sakaguchi, Yoshiro Chuman, Yasuo Akebiyama, Miho Matsukizono, Maki Watanabe, Junichi Tsutsumi
-
Patent number: 8053563Abstract: The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or pharmaceutical compositions for treatment of a disease wherein inhibition of cell growth, cell differentiation, remodelling of extracellular matrix, metastasis and/or induction of cell death due to apoptosis is a prerequisite for successful curing. An antibody of the invention is capable of inhibiting biological function of YKL-40 in the above mentioned processes by binding to a specific epitope on YKL-40.Type: GrantFiled: February 16, 2006Date of Patent: November 8, 2011Assignee: BIO-Y A/SInventors: Richard Bonnichsen, Paul Price
-
Publication number: 20110271357Abstract: The present invention provides a method for diagnosing and detecting diseases associated with colon. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in colon diseases (CCAT) and antibodies binds to CCAT. The present invention provides that CCAT is used as targets for screening agents that modulates the CCAT activities. Further the present invention provides methods for treating diseases associated with colon.Type: ApplicationFiled: October 25, 2010Publication date: November 3, 2011Applicant: CELERA CORPORATIONInventors: Yeounjin KIM, Tao HE, Steve RUBEN
-
Patent number: 8034904Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: December 8, 2003Date of Patent: October 11, 2011Assignee: Immunogen Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Publication number: 20110236393Abstract: The presently disclosed subject matter provides methods of inhibiting a host innate response to activator-mediated proliferative signals in a primary B cell. In some embodiments a method is provided for immortalized primary B cells. In some embodiments a method is provided for increasing efficiency of EBV transformation of primary B cells. In some embodiments a method is provided for increasing proliferation of primary B cells in culture. In some embodiments a method is provided for producing a monoclonal antibody. In some embodiments a method is provided for identifying a novel broadly neutralizing antibody having a desired antigen specificity. Also provided are antibodies produced according the methods of the presently disclosed subject matter.Type: ApplicationFiled: November 4, 2009Publication date: September 29, 2011Inventors: Kwan-ki Hwang, Micah Luftig
-
Patent number: 8012470Abstract: According to the invention there is described a method for ex vivo immunization of humans and animals comprising the following steps of: a) isolating autologous tumor cells; b) treating the tumor cells to prevent the survival thereof following reinfusion; c) incubating the thus treated tumor cells with intact heterologous bispecific and/or trisepcific antibodies showing the following properties: ?—binding to a T cell; ?—binding to at least one antigen on a tumor cell; ?—binding, by their Fc portion (in the case of bispecific antibodies), or by a third specificity (in the case of trispecific antibodies) to Fc receptor-positive cells.Type: GrantFiled: July 20, 2005Date of Patent: September 6, 2011Assignee: Helmholtz Zentrum Munchen Deutsches Forschungszentrum fur Gesundheit und Umwelt (GmbH)Inventors: Horst Lindhofer, Hans-Joachim Kolb, Reinhard Zeidler, Georg Bornkamm
-
Patent number: 8013128Abstract: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.Type: GrantFiled: March 4, 2009Date of Patent: September 6, 2011Assignee: Agensys, Inc.Inventors: Jean Gudas, Aya Jakobovits, Xiao-chi Jia, Robert Kendall Morrison, Karen Jane Meyrick Morrison, Hui Shao, Pia M. Challita-Eid, Arthur B. Raitano
-
Patent number: 8012945Abstract: A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. The method includes the steps of: (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are therapeutic and diagnostic methods using targeting ligands that bind an irradiated tumor.Type: GrantFiled: December 10, 2007Date of Patent: September 6, 2011Assignee: Vanderbilt UniversityInventors: Dennis E. Hallahan, Raymond Mernaugh
-
Patent number: 8003761Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: January 22, 2008Date of Patent: August 23, 2011Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa A. Popp
-
Patent number: 7993647Abstract: The present invention provides monoclonal antibodies to HIV-1 Vpr and hybridoma cell lines that produce the monoclonal antibodies to HIV-1 Vpr. Methods for use of such antibodies in the detection of HIV-1 infection are also provided.Type: GrantFiled: June 22, 2005Date of Patent: August 9, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Jeffrey B. Kopp, Terence M. Phillips, Ulrich Schubert, John Yewdell
-
Publication number: 20110189179Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: ApplicationFiled: April 13, 2011Publication date: August 4, 2011Inventors: Ugur Sahin, Özlzem Türeci, Michael Koslowski, Dirk Usener
-
Patent number: 7985842Abstract: Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: GrantFiled: November 24, 2008Date of Patent: July 26, 2011Assignee: Immunogen Inc.Inventors: Rajeeva Singh, Daniel J. Tavares, Nancy E. Dagdigian
-
Patent number: 7981416Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.Type: GrantFiled: March 18, 2009Date of Patent: July 19, 2011Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Patent number: 7981421Abstract: An antibody of the invention interacts with human DR5 or with human DR4 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Methods and uses for the antibodies, optionally in combination with various therapeutic agents, are detailed, including treatment of apoptosis-related disease and treatment of dysregulated cell growth.Type: GrantFiled: January 13, 2010Date of Patent: July 19, 2011Assignee: The UAB Research FoundationInventors: Tong Zhou, Kimihisa Ichikawa, Robert P. Kimberly, William J. Koopman, Jun Ohsumi, Albert F. LoBuglio, Donald J. Buchsbaum
-
Patent number: 7982015Abstract: The present invention concerns compositions and methods for the treatment of disorders characterized by the overexpression of an LIV-1. More specifically, the compositions include DNA and amino acid sequences of an LIV-1, antibodies to an LIV-1, and methods for the treatment of a mammal susceptible to or diagnosed with cancer wherein an LIV-1 is overexpressed.Type: GrantFiled: May 2, 2005Date of Patent: July 19, 2011Assignee: Genentech, Inc.Inventors: Fred de Sauvage, Audrey Goddard, Austin L. Gurney, Jo-Anne Hongo, Victoria Smith
-
Patent number: 7977462Abstract: The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.Type: GrantFiled: April 18, 2008Date of Patent: July 12, 2011Assignee: Cell Signaling Technology, Inc.Inventors: Peter Hornbeck, Ailan Guo, Ting-Lei Gu, Klarisa Rikova, Albrecht Moritz, Charles Farnsworth, Matthew Stokes, Jian Yu, Erik Spek, Yu Li, Anthony Possemato, Jessica Cherry, Valerie Goss, Jeffrey Mitchell, John Rush, Corinne Michaud
-
Publication number: 20110158902Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.Type: ApplicationFiled: January 24, 2011Publication date: June 30, 2011Applicant: NEOGENIX ONCOLOGY, INC.Inventors: Myron ARLEN, J. Andrew Bristol, Ariel C. Hollinshead, Kwong Y. Tsang
-
Patent number: 7968688Abstract: The present invention relates to a novel human gene that is differentially expressed in human carcinoma. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named C35 that is overexpressed in human breast and bladder carcinoma. This invention also relates to C35 polypeptide, in particular C35 peptide epitopes and C35 peptide epitope analogs, as well as vectors, host cells, antibodies directed to C35 polypeptides, and the recombinant methods for producing the same. The present invention further relates to diagnostic methods for detecting carcinomas, including human breast carcinomas. The present invention further relates to the formulation and use of the C35 gene and polypeptides, in particular C35 peptide epitopes and C35 peptide epitope analogs, in immunogenic compositions or vaccines, to induce antibody or cell-mediated immunity against target cells, such as tumor cells, that express the C35 gene.Type: GrantFiled: January 8, 2009Date of Patent: June 28, 2011Assignee: University of RochesterInventors: Maurice Zauderer, Elizabeth E. Evans
-
Patent number: 7968093Abstract: This invention relates to human antibodies that bind to human insulin-like growth factor-1 receptor (IGF-IR), to derivatives of these antibodies (Fabs, single chain antibodies, bi-specific antibodies, or fusion proteins), and to uses of the antibodies and derivatives in therapeutic, and diagnostic methods. The invention relates to nucleic acids encoding the anti-IGF-IR, methods of generating the antibodies and expression. The invention further relates to combination therapies using ant-IGF-IR antibodies with anti-neoplastic drugs.Type: GrantFiled: December 17, 2009Date of Patent: June 28, 2011Assignee: ImClone LLCInventor: Dale L Ludwig
-
Patent number: 7959915Abstract: The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells.Type: GrantFiled: September 12, 2005Date of Patent: June 14, 2011Assignee: Tufts UniversityInventors: Daniel G. Jay, Brenda K. Eustace, Takashi Sakurai
-
Patent number: 7947812Abstract: The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.Type: GrantFiled: March 15, 2004Date of Patent: May 24, 2011Assignee: Patrys LimitedInventors: Hans-Konrad Mueller-Hermelink, Heinz Peter Vollmers
-
Patent number: 7947459Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high'degree of structural conservation among them but show no significant structural homology to any known human proteins. STEAP-2 is a 454 amino acid protein characterized by a predicted molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.Type: GrantFiled: January 6, 2004Date of Patent: May 24, 2011Assignee: Agensys, Inc.Inventors: Rene S. Hubert, Arthur B. Raitano, Douglas Saffran, Daniel E. H. Afar, Steven Chappell Mitchell, Mary Faris, Aya Jakobovits
-
Patent number: 7943742Abstract: The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize ?v?6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-?v?6 antibodies of the invention. The invention also relates to the identification of differential expression of the integrin ?v?6 on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin ?v?6.Type: GrantFiled: July 10, 2006Date of Patent: May 17, 2011Assignee: Biogen Idec MA Inc.Inventors: Shelia M. Violette, Louise A. Koopman, Kenneth J. Simon, Paul H. Weinreb, Herman W. T. van Vlijmen, Jose W. Saldanha, Alexey A. Lugovskoy
-
Patent number: 7935791Abstract: The present invention relates to antagonist antibodies that specifically bind to Notch 3 and inhibit its activation. The present invention includes antibodies binding to a conformational epitope comprising the first Lin12 domain and the second dimerization domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.Type: GrantFiled: December 17, 2007Date of Patent: May 3, 2011Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Kang Li, Yucheng Li, Sanjaya Singh, Bin-Bing Stephen Zhou
-
Publication number: 20110091466Abstract: The present invention provides monoclonal IgE antibodies comprising Fc epsilon (?) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).Type: ApplicationFiled: October 7, 2010Publication date: April 21, 2011Inventors: MANUEL L. PENICHET, BIRGIT C. SCHULTES, CHRISTOPHER F. NICODEMUS, TRACY R. DANIELS, GUSTAVO HELGUERA, JOSE A. RODRIGUEZ
-
Patent number: 7919273Abstract: The present invention provides substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments thereof and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments thereof. The antibodies, fusion proteins or fragments are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Amino acid substitutions, particularly substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), result in improved therapeutic properties, such as decreased dissociation rates, improved CDC activity, improved apoptosis, improved B-cell depletion and improved therapeutic efficacy at very low dosages.Type: GrantFiled: July 21, 2009Date of Patent: April 5, 2011Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Chien-Hsing Chang, Hans J. Hansen
-
Patent number: 7919607Abstract: The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.Type: GrantFiled: May 28, 2009Date of Patent: April 5, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Publication number: 20110076763Abstract: The present invention features polypeptides, such as antibodies, and their use in the treatment and diagnosis of neoplasms.Type: ApplicationFiled: August 17, 2010Publication date: March 31, 2011Applicant: PATRYS LIMITEDInventors: HEINZ PETER VOLLMERS, Hans Konrad Mueller-Hermelink
-
Patent number: 7915390Abstract: The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders.Type: GrantFiled: October 18, 2007Date of Patent: March 29, 2011Assignee: Genentech, Inc.Inventors: Kang Li, Bin-Bing Stephen Zhou, Wenjuan Wu, Sek Chung Fung, Sanjaya Singh
-
Patent number: 7915396Abstract: Humanized anti-TAG-72 CC49 monoclonal antibodies are disclosed herein. The antibodies include a light chain Complementarity Determining Region (L-CDR)1, a L-CDR2, and a L-CDR3; and a heavy chain Complementarity Determining Region (H-CDR)1, a H-CDR2, and a H-CDR3 from humanized antibody HuCC49V10. The L-CDR1, L-CDR2, L-CDR3 are within a HuCC49V10 light chain framework region that includes the corresponding amino acid from LEN at position 5, 19, 21, and 106 in the light chain. The H-CDR1, H-CDR2, and H-CDR3 are within a heavy chain HuCC49V10 framework comprising a human 21/28? CL residue at positions 20, 38, 48, 66, 67, 69, and 80 in the heavy chain. These humanized CC49 antibodies retain binding affinity for TAG-72 and have reduced immunogenicity, as compared to a parental HuCC49V10 antibody. Methods are disclosed herein for using these antibodies in the treatment or diagnosis of a tumor, such as a carcinoma, expressing TAG-72.Type: GrantFiled: August 20, 2009Date of Patent: March 29, 2011Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Syed V. S. Kashmiri, Jeffrey Schlom, Eduardo A. Padlan
-
Publication number: 20110071073Abstract: A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided.Type: ApplicationFiled: November 2, 2006Publication date: March 24, 2011Applicant: Illumigen Biosciences, Inc.Inventors: Shawn P. Iadonato, Charles L. Magness, Gary Rosenberg, Christina A. Scherer
-
Patent number: 7906118Abstract: The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody.Type: GrantFiled: April 6, 2009Date of Patent: March 15, 2011Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi